Skip to main content

Breast Cancer Research

Ausgabe Sonderheft 1/2003

24th Congress of the International Association for Breast Cancer Research. Advances in human breast cancer research: preclinical models

Inhalt (63 Artikel)

Oral presentation

Estrogen receptor alpha-positive and negative mouse mammary tumors through somatic mutations of p53 in mammary carcinogenesis

S-CJ Lin, K-F Lee, AY Nikitin, KM Bushnell, SG Hilsenbeck, RD Cardiff, A Li, K-W Kang, SA Frank, W-H Lee, EY-HP Lee

Oral presentation

Mouse models for BRCA1-associated breast cancer

R-H Wang, W Li, X Xu, C Deng

Oral presentation

Integrin-mediated signal transduction in transgenic mouse models of human breast cancer

DE White, S Blaess, U Mueller, S Dedhar, RD Cardiff, R St Arnaud, WJ Muller

Oral presentation

Reversibility and progression in conditional transgenic mouse models of breast cancer

LA Chodosh, RB Boxer, SE Moody, BA Keister, CJ Sarkisian, JW Jang, GK Belka, CM Blakely, CP Portocarero, CJ Sterner, KL Notarfrancesco, EA Kauh

Oral presentation

Advanced immunophenotyping: more is better!

N Baumgarth

Oral presentation

Whole Slide Imaging and telepathology

J Galvez

Oral presentation

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors

RH Schwall, P Hollingshead, S Erickson, J Winer, M Williams, D Dugger

Oral presentation

Use of mouse models to validate and therapeutically target transforming growth factor beta as an important player in breast cancer progression

LM Wakefield, Y Yang, O Dukhanina, B Tang, M Mamura, JL Letterio, J Green, GT Merlino, MR Anver

Oral presentation

Development of a transgenic mouse line for the evaluation of the androgen receptor activity in vivo

R Attar, C Cullinan, C-P Ho, M Swerdel, J Dell, RB Rowley, DJ Bol, J Ostrowski, K Mookhtiar, M Gottardis, R Weinmann

Oral presentation

Clinical breast cancer and estrogen

HK Chew

Oral presentation

Pregnancy levels of estrogen prevents breast cancer

S Nandi, RC Guzman, G Thordarson, L Rajkumar

Oral presentation

The molecular biology of mammary intraepithelial neoplasia outgrowths

L Namba, SY Liu, ET McGoldrick, LJT Young, AD Borowsky, RD Cardiff, JP Gregg

Oral presentation

The comparative genetics and genomics of cancer: of mice and men

G Hodgson, J Hager, K Chin, CA Lapuk, S Volik, C Collins, A Balmain, F Waldman, D Hanahan, J Gray

Oral presentation

Genetic determinants of susceptibility to estrogen-induced mammary cancer in the rat

JD Shull, BS Schaffer, LM Bartsch, LK Buckles, KA Gould, M Tochacek, B Xie, CM Lachel, KL Pennington, TE Strecker, KK Hansen

Oral presentation

Function of LEF1 in early mammary development

K Kratochwil, S Tontsch, R Grosschedl

Oral presentation

Using genomic similarities and differences to interpret mouse models of human development and cancer

L Stubbs, C Elso, G Loots, A Hamilton, I Ovcharenko

Oral presentation

Imaging mouse models of breast cancer with positron emission tomography

S Cherry, C Abbey, S Borowsky, J Gregg, R Cardiff

Oral presentation

Imaging angiogenesis in early stages of breast cancer using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor

S Mandl, FG Blankenberg, Y-A Cao, C O'Connell-Rodwell, C Mari, TI Gaynutdinov, J-L Vanderheyden, MV Backer, JM Backer, C Contag

Oral presentation

Ultrasound imaging of tumor perfusion

K Ferrara, P Dayton, R Pollard, A Broumas, E Wisner

Oral presentation

Preneoplasia in mouse models

D Medina

Oral presentation

Regulation of human mammary stem cells

RB Clarke, E Anderson, A Howell, H Okano, CS Potten

Oral presentation

Characterization, isolation and cultivation of distinctive human breast cell populations

R Villadsen, T Gudjonsson, A Fridriksdottir, M Wissing, L Rønnov-Jessen, MJ Bissell, OW Petersen

Oral presentation

Stem cells in normal breast development and breast cancer

MS Wicha, G Dontu, M Al-Hajj, MF Clarke

Oral presentation

Functional characterization of mammary stem cells in development and breast cancer

JM Rosen, BE Welm, SB Tepera, F Behbod, SL Grimm, T Venezia, MA Goodell, TA Graubert, Z Werb, Y Li, HE Varmus

Oral presentation

Prevention of breast tumor angiogenesis and metastasis by cytostatic molecules in relevant mouse models

M Crépin, M DiBenedetto, R Bagheri-Yarmand, A Starzec, R Vassy, G Perret

Oral presentation

Immunotherapy of cancer

I McKenzie

Oral presentation

Mouse models for pretesting of immunotherapeutic strategies for cancer patients

JM Burchell, DW Miles, A Mungul, T Plunkett, R Sewell, G Picco, I Correa, J Taylor-Papadimitriou

Oral presentation

Target discovery in the postgenomic era

L Friedman, L Johnson, H Francis-Lang, M Costa, D Baly, G Duyk, G Plowman

Oral presentation

From gene expression patterns to antibody diagnostics

DT Ross, BZ Ring, S Chang, Y Wang, C McDaniel, S Defoe, R Beck, R Seitz

Oral presentation

Combined hormonal therapy for advanced breast cancer in postmenopausal patients

P Langecker, W Lang, D Blanchett, P Bailey, C Scribner, P Goss

Oral presentation

CTLA-4 based therapy (MDX-010)

A Korman

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.